Manash K. Paul

Manash K. Paul


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2025 in Stem Cell Reviews and Reports
Verified
Journal Article
Closed access
PDF file
MBMansoor Bolideei
Mansoor Bolideei
RBRambod Barzigar
Rambod Barzigar
RGRazieh Bahrami Gahrouei
Razieh Bahrami Gahrouei
EMElham Mohebbi
Elham Mohebbi
KHKhawaja Husnain Haider
Khawaja Husnain Haider
MMMohammad Javad Mehran
Mohammad Javad Mehran

28 October 2024 in Cells
Verified
Journal Article
Open access
PDF file
DGDamayanti Das Ghosh
Damayanti Das Ghosh
Hannah McDonaldHannah McDonald
Hannah McDonald
RDRajeswari Dutta
Rajeswari Dutta
KKKeerthana Krishnan
Keerthana Krishnan
JTJaya Thilakan
Jaya Thilakan
VRVivek M Rangnekar
Vivek M Rangnekar
Non-small cell lung cancer (NSCLC) has established predictive biomarkers that enable decisions on treatment regimens for many patients. However, resistance to therapy is widespread. It is therefore essential to have a panel of molecular biomarkers that may help overcome therapy resistance and prevent adverse effects of treatment. We performed in silico analysis of NSCLC prognostic indicators, separately for adenocarcinomas and squamous carcinomas, by using The Cancer Genome Atlas (TCGA) and non-TCGA data sources in cBioPortal as well as UALCAN. This review describes lung cancer biology, elaborating on the key genetic alterations and specific genes responsible for resistance to conventional treatments. Importantly, we examined the mechanisms associated with resistance to immune checkpoint inhibitors. Our analysis indicated that a robust prognostic biomarker was lacking for NSCLC, especially for squamous cell carcinomas. In this work, our screening uncovered previously unidentified prognostic gene expression indicators, namely, MYO1E, FAM83 homologs, and DKK1 for adenocarcinoma, and FGA and TRIB1 for squamous cell carcinoma. It was further observed that overexpression of these genes was associated with poor prognosis. Additionally, FAM83 homolog and TRIB1 unexpectedly harbored copy number amplifications. In conclusion, this study elucidated novel prognostic indicators for NSCLC that may serve as targets to overcome therapy resistance toward improved patient outcomes.

8 March 2025 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
SGSharon George
Sharon George
HSHendry Saju
Hendry Saju
TJTharun Jaikumar
Tharun Jaikumar
RRReshma Raj
Reshma Raj
RNR. Nisarga
R. Nisarga
RARohidas Arote
Rohidas Arote

16 June 2026 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
PPPalla Ranga Prasad
Palla Ranga Prasad
PSPraveen Kumar Sahni
Praveen Kumar Sahni
DMDebadrita Mondal
Debadrita Mondal
KVKirthanashri S. Vasanthan
Kirthanashri S. Vasanthan
SVS. Varadharajan
S. Varadharajan
MPManash K. Paul
Manash K. Paul
Tracheal damage arising from inflammation, trauma, congenital anomalies, or tumors can lead to life-threatening complications, yet current treatments, including surgical reconstruction, stenting, laser therapies, autografts, and allografts, remain inadequate, especially for long-segment defects. As a result, tracheal tissue engineering has emerged as a promising alternative, aiming to create functional biomimetic constructs that reduce dependence on complex surgeries, long-term stenting, and immunosuppression. Advances in additive manufacturing and 3D bioprinting have accelerated progress toward engineered tracheal substitutes; however, a fully functional, clinically viable 3D-bioprinted human tracheal graft has yet to be realized. This review assesses current bioengineering strategies, with a particular emphasis on the interplay between cell sources, scaffold materials, and fabrication methods, specifically focusing on 3D bioprinted tracheal constructs. Across existing studies, the most promising direction lies in multi-material, multicellular, spatially patterned bioprinting approaches that can better recapitulate the trachea’s complex biomechanics and heterogeneous tissue composition. Finally, we summarize regulatory considerations and outline key scientific and translational barriers, emphasizing that overcoming challenges in vascularization, innervation, and long-term functional integration will be essential to achieving a physiologically aligned, clinically deployable tracheal substitute.

18 July 2026 in Cancers
Verified
Journal Article
Open access
PDF file
SKSravya Kankipati
Sravya Kankipati
Kanchan ShindeKanchan Shinde
Kanchan Shinde
MPManash K. Paul
Manash K. Paul
SMSubhadip Mukhopadhyay
Subhadip Mukhopadhyay
Cancer continues to be a primary cause of death globally, necessitating the constant development of effective and less toxic therapeutics. Cucurbitacins belong to the tetracyclic triterpenoids found mainly in the Cucurbitaceae family. Cucurbitaceae plants exert various biological activities such as anti-diabetic, anti-cancer and anti-inflammatory properties, which make them beneficial in addressing metabolic disorders. This review focuses on cucurbitacins namely A, B, C, D, E, I, IIa, which have been explored in cancer research. Cucurbitacins suppress tumor progression by activating cell death pathways, including apoptosis, autophagy, pyroptosis and ferroptosis. They are known to target multiple crucial biomolecular key players, such as STAT3, AKT, mTOR, ERK, EGFR and TLR4. Additionally, they disrupt cytoskeletal proteins and inhibit cell proliferation, invasion, migration, angiogenesis, and cell-cycle arrest. Cucurbitacins have been demonstrated to modulate tumor microenvironment, leading to enhanced host immune surveillance that reverses traditional therapy resistance from cisplatin, doxorubicin, and paclitaxel. In this review, we highlight the strong potential of cucurbitacins as anti-cancer agents, either as monotherapy or in combination, for the development of safer, cost-effective drugs with improved patient treatment outcomes.

24 September 2025
Verified
Book Chapter
Open access
PDF file
MPManash K. Paul
Manash K. Paul
BSBhisham Narayan Singh
Bhisham Narayan Singh
BBBharti Bisht
Bharti Bisht
Open access peer-reviewed chapter